Boston Scientific Corp. vs Eli Lilly & Co.
BSX vs LLY — side-by-side comparison from reported financials. BSX leads 3, LLY leads 9 of 12 comparable metrics.
Boston Scientific Corp.
BSX · Healthcare
$42.62+1.37%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | BSX | LLY |
|---|---|---|
| Price | $42.62 | $1 177.20 |
| Market cap | $61.8B | $1.05T |
| Revenue (TTM) | $21.0B | $79.7B |
| Revenue growth | +16.5% | +31.7% |
| Net margin | 17.5% | 33.5% |
| Free cash flow | $3.63B | $18.2B |
| Net cash (debt) | ($9.47B) | ($35.2B) |
| 1-year price return | -56.2% | +37.6% |
| P/E | 16.9 | 41.6 |
| P/E vs own history (cheap-side %) | 99% | 88% |
| Dividend yield | 0.00% | 0.52% |
| Return on equity | 15% | 93% |
| Altman Z-score | 2.58 | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 59,000 | 50,000 |
Full résumé-style profiles: BSX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.